Literature DB >> 6500511

Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis.

J Bosch, R Masti, D Kravetz, J Bruix, J Gaya, J Rigau, J Rodes.   

Abstract

The effects of propranolol on blood flow through gastroesophageal collaterals and on systemic and hepatic hemodynamics were investigated in 23 cirrhotic patients with portal hypertension. Gastroesophageal collateral blood flow was evaluated by the measurement of azygos venous blood flow by continuous thermal dilution. Azygos venous blood flow was markedly increased in these patients (544 +/- 48 ml per min, as compared with 132 +/- 18 ml per min in subjects without portal hypertension (p less than 0.001). Propranolol at doses achieving effective beta-blockage (83 +/- 5 mg) (mean +/- S.E.M.) markedly reduced azygos venous blood flow (to 354 +/- 34 ml per min, p less than 0.001). Reduction of azygos venous blood flow (-34.2 +/- 3.6%) was significantly greater (p less than 0.01) than reductions in cardiac output (-22.6 +/- 1.9%), hepatic venous pressure gradient (-11.5 +/- 2.4%) and hepatic blood flow (-13.4 +/- 7.4%). The hemodynamic effects of propranolol were not related to plasma norepinephrine levels. Reduction of gastroesophageal collateral blood flow may be the mechanism by which oral propranolol therapy reduces the risk of repeated episodes of variceal bleeding in cirrhotic patients with portal hypertension.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6500511     DOI: 10.1002/hep.1840040617

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

Review 1.  Long term management of oesophageal varices.

Authors:  S K Sarin
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 2.  Pathophysiology of portal hypertension and its clinical links.

Authors:  Yeon Seok Seo; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

3.  Computerised system for the continuous measurement of azygos venous blood flow.

Authors:  P C Hayes; D Terrace; I Peaston; I A Bouchier; D Redhead; H M Brash
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

Review 4.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

5.  Assessment of the hepatic microvascular changes in liver cirrhosis by perfusion computed tomography.

Authors:  Mai-Lin Chen; Qing-Yu Zeng; Jian-Wei Huo; Xiao-Ming Yin; Bao-Ping Li; Jian-Xin Liu
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

6.  Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis.

Authors:  S Sugano; T Kawafune; T Okajima; K Ishii; M Watanabe; N Takamura
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 7.  Portal vein thrombosis in cirrhosis: Controversies and latest developments.

Authors:  Damian J Harding; M Thamara P R Perera; Frederick Chen; Simon Olliff; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

8.  Effects of non-shunting operation on azygos venous blood flow in cirrhotic patients.

Authors:  N Kokudo; S Kawasaki; K Ohashi; H Sakamoto; H Koyama; K Sanjo; Y Idezuki
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

9.  Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. Transjugular intrahepatic portosystemic shunt.

Authors:  L Bellis; E Moitinho; J G Abraldes; M Graupera; J C García-Pagán; J Rodés; J Bosch
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

10.  Postprandial vascular response in patients with cirrhosis. Short-term effects of propranolol administration.

Authors:  D Alvarez; C Miguez; A Podesta; R Terg; A Sanchez Malo; J C Bandi; S Sanchez; R Mastai
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.